NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 120 filers reported holding NURIX THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $250,946 | -23.2% | 31,927 | -2.4% | 0.00% | 0.0% |
| Q2 2023 | $326,733 | +104287.5% | 32,706 | -7.1% | 0.00% | 0.0% |
| Q1 2023 | $313 | -6.3% | 35,215 | +15.8% | 0.00% | 0.0% |
| Q4 2022 | $334 | -99.9% | 30,403 | +1.3% | 0.00% | -50.0% |
| Q3 2022 | $391,000 | +3.2% | 30,006 | +0.4% | 0.00% | 0.0% |
| Q2 2022 | $379,000 | -7.1% | 29,897 | +2.7% | 0.00% | 0.0% |
| Q1 2022 | $408,000 | -51.4% | 29,124 | +0.4% | 0.00% | -50.0% |
| Q4 2021 | $840,000 | -3.3% | 29,018 | +0.1% | 0.00% | -20.0% |
| Q3 2021 | $869,000 | – | 29,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 327,123 | $4,583,000 | 10.17% |
| TRV GP III, LLC | 1,922,549 | $26,935,000 | 7.31% |
| Ponoi Management, LLC | 327,122 | $4,583,000 | 5.95% |
| Foresite Capital Management IV, LLC | 1,030,798 | $14,441,000 | 4.04% |
| DAFNA Capital Management LLC | 543,344 | $7,612,000 | 1.98% |
| Soleus Capital Management, L.P. | 1,011,638 | $14,173,000 | 1.83% |
| Bain Capital Life Sciences Investors, LLC | 1,284,313 | $17,993,000 | 1.75% |
| Redmile Group, LLC | 3,018,784 | $42,293,000 | 1.32% |
| WestHill Financial Advisors, Inc. | 283,333 | $3,969,000 | 1.14% |
| Boxer Capital, LLC | 1,224,892 | $17,161,000 | 0.88% |